- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of September 2
The Center for Biosimilars® recaps the top stories for the week of September 2, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of September 2, 2019.
Number 5: At Amgen’s request, the Patent Trial and Appeal Board will review several key patents on Alexion’s Soliris.
Number 4: Canada’s regulatory body recently updated its fact sheet on biosimilars, including new or clarified information about key topics such as switching.
Number 3: England’s National Health Service says that it has saved the equivalent of $134 million on adalimumab after Humira lost patent protection in 2018.
Number 2: The FDA has given Mylan and Biocon a second Complete Response Letter for their follow-on insulin glargine.
Number 1: Biosimilars for multiple sclerosis drugs are now on the horizon after Sandoz announced its plan to commercialize a biosimilar natalizumab.
Finally, last week, our e-newsletter asked whether you agree with a new treatment guideline that recommends that stable patients not be required to switch to biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
